Print Email

Recent Publications by Members of the Hemostasis Study Group


Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry. Frere C, Trujillo-Santos J, Font C, Sampériz Á, Quintavalla R, González-Martínez J, Vázquez FJ, Lima J, Farge D, Monreal M; RIETE Investigators. Thromb Haemost. 2018 Apr 21. [Epub ahead of print]

Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Muñoz Martín AJ, Ortega I, Font C, Pachón V, Castellón V, Martínez-Marín V, Salgado M, Martínez E, Calzas J, Rupérez A, Souto JC, Martín M, Salas E, Soria JM. Br J Cancer. 2018 Apr;118(8):1056-1061.

Patients' Experience of Living with Cancer-associated thrombosis in Spain (PELICANOS). Font C, Nelson A, Garcia-Fernandez T, Prout H, Gee P, Noble S. Support Care Cancer. 2018 Apr 7. [Epub ahead of print]

The role of direct oral anticoagulants in cancer-related venous thromboembolism: a perspective beyond the guidelines. Rojas-Hernandez CM. Support Care Cancer. 2018 Mar;26(3):711-720. Review.

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators. N Engl J Med. 2018 Feb 15;378(7):615-624.

Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a Comprehensive Cancer Center. Khan M, Cox TM, Nassif M, Alzubaidi MA, Garg N, Qiao W, Aung FM, Oo TH, Rojas-Hernandez CM. J Thromb Thrombolysis. 2018 Feb 7. [Epub ahead of print]

The prognostic impact of additional intrathoracic findings in patients with cancer-related pulmonary embolism. Jiménez-Fonseca P, Carmona-Bayonas A, Font C, Plasencia-Martínez J, Calvo-Temprano D, Otero R et al.; EPIPHANY study investigators and the Asociación de Investigación de la Enfermedad Tromboembólica de la Región de Murcia. Clin Transl Oncol. 2018 Feb;20(2):230-242.

Discharge or admit? Emergency department management of incidental pulmonary embolism in patients with cancer: A retrospective study. Banala SR, Yeung S-C J, Rice TW, Reyes-Gibby CC, Wu CC, Todd KH et al. Int J Emerg Med. 2017 Dec;10(1):19.  Free PMC Text

Frequency of venous thromboembolism events during acute inpatient rehabilitation in a comprehensive cancer centre. Ng AH, Goldman L, Fu JB, Oo TH, Chisholm GB, Liu DD, Bedi A, Bruera E. J Rehabil Med. 2017 Nov 21;49(9):758-764. Free Article

Primary thromboprophylaxis (PTP) in ambulatory patients with lung cancer receiving chemotherapy: A systematic review and meta-analysis of randomized controlled trials (RCTs). Thein KZ, Yeung SJ, Oo TH. Asia Pac J Clin Oncol. 2017 Sep 26. [Epub ahead of print]

Performance of 4T score and heparin-platelet factor 4 antibody in the diagnosis of heparin-induced thrombocytopenia (HIT) in cancer. Wong M, Oo TH, Qiao W, Garg N, Rojas-Hernandez CM. J Thromb Thrombolysis. 2017 Aug;44(2):261-266.

Low discriminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry. Alatri A, Mazzolai L, Font C, Tafur A, Valle R, Marchena PJ, Ballaz A, Tiraferri E, Font L, Monreal M; RIETE Investigators. Thromb Haemost. 2017 May 18.  [Epub ahead of print]

Venous thromboembolism in radiation therapy cancer patients: Findings from the RIETE registry. Guy JB, Bertoletti L, Magné N, Rancoule C, Mahé I, Font C, Sanz O, Martín-Antorán JM, Pace F, Vela JR, Monreal M; RIETE investigators. Crit Rev Oncol Hematol. 2017 May;113:83-89.

Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index. Carmona-Bayonas A, Jiménez-Fonseca P, Font C, Fenoy F, Otero R, Beato C, et al.  Br J Cancer. 2017 Apr 11;116(8):994-1001.

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. Fernandez-Martinez A, Pascual T, Perrone G, Morales S, de la Haba J, González-Rivera M, et al. Oncotarget. 2017 Mar 28;8(13):21930-21937.  Free PMC Article

The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site. Mahé I, Chidiac J, Bertoletti L, Font C, Trujillo-Santos J, Peris M et al; RIETE investigators. Am J Med. 2017 Mar;130(3):337-347.

Prognostic value of computed tomography pulmonary angiography indices in patients with cancer-related pulmonary embolism: Data from a multicenter cohort study. Plasencia-Martínez JM, Carmona-Bayonas A, Calvo-Temprano D, Jiménez-Fonseca P, Fenoy F, Benegas M, Sánchez M, Font C et al. Eur J Radiol. 2017 Feb;87:66-75.

Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis. Rojas-Hernandez CM, Oo TH, García-Perdomo HA. J Thromb Thrombolysis. 2017 Feb;43(2):233-240.

Vasculitic neuropathy induced by pembrolizumab. Aya F, Ruiz-Esquide V, Viladot M, Font C, Prieto-González S, Prat A, Arance A. Ann Oncol. 2017 Feb 1;28(2):433-434. 

"Post-thrombotic panic syndrome": A thematic analysis of the experience of venous thromboembolism. Hunter R, Lewis S, Noble S, Rance J, Bennett PD. Br J Health Psychol. 2017 Feb;22(1):8-25.

Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis. Ross JA, Miller MM, Rojas Hernandez CM. Thromb Res. 2017 Feb;150:86-89.

FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence. Jimenez-Fonseca P, Carmona-Bayonas A, Calderon C, Fontcuberta Boj J, Font C, Lecumberri R et al.Clin Transl Oncol. 2017 Feb 27. [Epub ahead of print]

Prospective cohort study of cancer patients diagnosed with incidental venous thromboembolism on routine computed tomography scans. Escalante CP, Gladish GW, Qiao W, Zalpour A, Assylbekova B, Gao S et al. Support Care Cancer. 2017 Jan 9. [Epub ahead of print]

Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism. Trujillo-Santos J, Martos FM, Font C, Farge-Bancel D, Rosa V, Lorenzo A et al. Heliyon. 2017 Jan 16;3(1):e00229. Free PMC Article

Prospective cohort study of cancer patients diagnosed with incidental venous thromboembolism on routine computed tomography scans. Escalante CP, Gladish GW, Qiao W, Zalpour A, Assylbekova B, Gao S et al. Support Care Cancer. 2017 Jan 9. [Epub ahead of print]

Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. Font C, Carmona-Bayonas A, Beato C, Reig Ò, Sáez A, Jiménez-Fonseca P et al.  Eur Respir J. 2017 Jan 4;49(1). pii: 1600282.

Sex Differences in Patients With Occult Cancer After Venous Thromboembolism. Jara-Palomares L, Otero R, Jiménez D, Praena-Fernández JM, Rivas A, Font C, Wells PS, López-Reyes R, González-Martínez J, Monreal M. Clin Appl Thromb Hemost. 2017 Jan 1:1076029617711805.

Symptoms, signs, suspicion and setting: a PESI score for cancer-associated pulmonary embolism? Posch F and Ay C. Eur Respir J. 2017 Jan 4;49(1). pii: 1602225. Editorial recommending Font C et al., Eur Respir J. 2017 Jan 4;49(1). Free PMC Article

Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. Peris M, Jiménez D, Maestre A, Font C, Tafur AJ, Mazzolai L et al; RIETE Investigators. Eur Respir J. 2016 Nov;48(5):1360-1368.

Factors influencing adherence to clinical guidelines in the management of cancer-associated thrombosis. Mahé I, Chidiac J, Helfer H, Noble S. J Thromb Haemost. 2016 Nov;14(11):2107-2113.

Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial. Lu H, Champlin RE, Popat U, Pundole X, Escalante CP, Wang X et al. Bonekey Rep. 2016 Oct 19;5:843

Thromboembolic disease and breathlessness. Noble S. Curr Opin Support Palliat Care. 2016 Sep;10(3):249-55.

Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. Zalpour A, Oo TH. Adv Hematol. 2015;2015:920361. [Epub Aug 16, 2015] Review. Free PMC Article

The novel oral anticoagulants. Rojas-Hernandez CM, Garcia DA. Semin Thromb Hemost. 2013 Mar;39(2):117-26. Review.

Prevention and treatment of venous thromboembolism with new oral anticoagulants: a practical update for clinicians.  Tun NM, Oo TH. Thrombosis. 2013;2013:183616. Epub 2013 Feb 21. Free PMC Article

On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism. Carmona-Bayonas A, Font C, Jiménez-Fonseca P, Fenoy F, Otero R, Beato C et al; Asociación de Investigación de la Enfermedad Tromboembólica de la Región de Murcia. Thromb Res. 2016 Jul;143:76-85.

Cancer Associated Thrombosis: Focus on Prevention and Treatment of Venous Thromboembolism. Thein KZ, Myint ZW, Tun AM, Oo TH. Cardiovasc Hematol Agents Med Chem. 2016 Jun 13. [Epub ahead of print]

Home management of acute medical complications in cancer patients: a prospective pilot study. Font C, Fernández-Avilés F, Calderon C, García-Fernández T, Arab N, Pineda E, et al.Support Care Cancer 2016 May;24(5):2129-37.

Patients' Experiences of LIving with CANcer associated thrOmbosis in Spain (PELICANOS). Font C, Garcia-Fernandez T, Nelson A, Prout H, Noble S. Thromb Res. 2016 Apr;140 Suppl 1:S199.

PO-25 - FATCAT: an observational cohort study investigating fractal dimension (df) as a biomarker of thrombogenicity in cancer associated thrombosis during chemotherapy for lung cancer. Davies NA, Noble S, Harrison NK, Morris RH, Evans PA. Thromb Res. 2016 Apr;140 Suppl 1:S185. 

Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Tun NM, Guevara E, Oo TH. Blood Coagul Fibrinolysis. 2016 Apr;27(3):270-4.

OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Young A, Phillips J, Hancocks H, Hill C, Joshi N, Marshal A et al. Thromb Res. 2016 Apr;140 Suppl 1:S172-3.

Phlegmasia cerulea dolens and multiple recurrent thrombotic events as the presenting feature of EML4-ALK translocated non-small cell lung cancer. Fernandez-Martinez A, Font C, Selvi M, Viladot M, Paré L, Galván P. et al.  Cancer Treatment Communications, 6(2016):4-7.

Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, et al. J Clin Oncol. 2016 Feb 10;34(5):488-94. 

Fractal dimension (df) as a new structural biomarker of clot microstructure in different stages of lung cancer. Davies NA, Harrison NK, Morris RH, Noble S, Lawrence MJ, D'Silva LA et al. Thromb Haemost. 2015 Nov 25;114(6):1251-9. 

Anticoagulating the subsegmental pulmonary embolism in cancer patients: a survey amongst different medical specialties. Lim WY, Bozas G, Noble S, Hart S, Maraveyas A. J Thromb Thrombolysis. 2015 Jul;40(1):37-41.

Application of ROTEM to assess hypercoagulability in patients with lung cancer. Davies NA, Harrison NK, Sabra A, Lawrence MJ, Noble S, Davidson SJ, et al. Thromb Res. 2015 Jun;135(6):1075-80.

Prediction of serious complications in patients with seemingly stable febrile neutropenia: Validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, et al.  J Clin Oncol. 2015 Feb 10;33(5):465-71.

[Pulmonary embolism in patients with cancer: foundations of the EPIPHANY study]  Font C, Carmona-Bayonas A, Plasencia JM, Calvo-Temprano D, Sánchez M, Jiménez-Fonseca P et al; en representación de los Investigadores del Proyecto EPIPHANY. Med Clin (Barc). 2015 Jan;144 Suppl 1:31-7.  Spanish.

Clinical guide SEOM on venous thromboembolism in cancer patients. Muñoz Martín AJ, Font Puig C, Navarro Martín LM, Borrega García P, Martín Jiménez M; Spanish Society for Medical Oncology. Clin Transl Oncol. 2014 Dec;16(12):1079-90.

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence. Zalpour A, Oo TH. Drug Des Devel Ther. 2014 Nov 5;8:2181-91. eCollection 2014. Review. Free PMC Article

Bacteremia in adult cancer patients with apparently stable febrile neutropenia: data from a cohort of 692 consecutive episodes from a single institution. Carmona-Bayonas A, Fonseca PJ, Font C, Martínez-García J, Torrella F, Urrego E, et al. J Community Support Oncol. 2014 Sep;12(9):312-20.

Primary thromboprophylaxis in hospices: the association between risk of venous thromboembolism and development of symptoms. Johnson MJ, McMillan B, Fairhurst C, Gabe R, Ward J, Wiseman J, Pollington B, Noble SI. J Pain Symptom Manage. 2014 Jul;48(1):56-64. 

Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G. 2014 May;22(5):1217-22.

Outpatient management of pulmonary embolism in cancer: Data on a prospective cohort of 138 consecutive patients. Font C, Carmona-Bayonas A, Fernández-Martinez A, Beato C, Vargas A, Gascon P, Otero R. J Natl Compr Canc Netw. 2014 Mar 1;12(3).

International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, et al. J Thromb Haemost. 2013 Jan;11(1):56-70. Review. Free Article

The ethical decisions UK doctors make regarding advanced cancer patients at the end of life--the perceived (in) appropriateness of anticoagulation for venous thromboembolism: a qualitative study. Sheard L, Prout H, Dowding D, Noble S, Watt I, Maraveyas A, Johnson M. BMC Med Ethics. 2012 Sep 4;13:22. Free PMC Article

Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? A qualitative study. Johnson MJ, Sheard L, Maraveyas A, Noble S, Prout H, Watt I, Dowding D. BMC Med Inform Decis Mak. 2012 Jul 20;12:75. Free PMC Article

Low-molecular-weight heparin and survival in lung cancer. Noble S. Thromb Res. 2012 Apr;129 Suppl 1:S114-8.